NASDAQ : OKYO

OKYO Pharma Limited

$1.49 USD

-$0.04 (-2.61%)

Volume
105.55K
Average Volume
75.05K
Market Capitalization
$57.17M
P/E Ratio
-6.23
Dividend Yield
0.00%
Price Target
$5.00
Year High
$3.33
Year Low
$1.34
Day High
—
Day Low
—
Payout Ratio
$0.00
Current Ratio
$2.43
Company Overview

NASDAQ

Robert J. Dempsey

Biotechnology

Healthcare

OKYO

5

GB

USD

https://www.okyopharma.com

44 20 7495 2379

679345108

0001849296

Liquidity Metrics

0.00

2.43

2.43

1.69

0.00

Sales & Valuation

-$

0.00

4.52

-9.62

-0.16

Profitability

-$0.24

-$8.95M

0.00%

0.00%

-200.67%

-42.67%

P/E Metrics

-6.23

0.05

0.05

Analyst Price Target & Rating

$5.00

$5.00

$5.00

Strong Sell

1/5

2 Analysts

-70.20%

Financial Health Scores

-7.93

2/9

$12.33M

$20.98M

$8.64M

-$15.63M

Key Metrics (TTM)

$42.57M

0.00

-4.63

2.43

-200.67%

-74.59%

-16.06%

-10.39%

-1431150 days

Company Executives
Name Title
Robert J. Dempsey Chief Executive Officer & Executive Director
Michael Paul Beck Founder
Rajkumar Patil Chief Scientific Officer
Flavio Mantelli Chief Medical Officer
Keeren Shah Chief Financial Officer
Gary S. Jacob Chief Development Officer & Director
Poll Results

No votes yet today — be the first to share your view!

About OKYO Pharma Limited (NASDAQ:OKYO) Stock

OKYO Pharma Limited is a biopharmaceutical firm operating at the preclinical stage, dedicated to developing innovative treatments for individuals in the United Kingdom experiencing inflammatory eye conditions and ocular discomfort. Its primary therapeutic candidate is OK-101, specifically designed to address dry eye disease. Additionally, the company is advancing OK-201, an experimental bovine adrenal medulla lipidated-peptide analogue, intended to treat neuropathic ocular pain. Established in 2007, OKYO Pharma Limited maintains its headquarters in London, UK. ...

OKYO Pharma Announces Purchase of Shares by Chief Scientific Officer

2026-07-28 07:00:00

LONDON and NEW YORK, July 28, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Raj Patil, PhD, Chief Scientific Officer of OKYO Pharma has increased his holdings with the purchase of 3,363 of the Company's ordinary shares on NASDAQ at $1.49 per share, bringing his total holding to 20,030 ordinary shares. About OKYO Pharma OKYO Pharma Limited (Nasdaq: OKYO) is a clinical-stage biopharmaceutical company developing innovative therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, with ordinary shares listed for trading on the Nasdaq Capital Market.

OKYO Pharma to Participate in the BTIG Biotechnology Conference 2026

2026-07-27 07:00:00

LONDON and NEW YORK, July 27, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced its participation in the BTIG Biotechnology Conference 2026 taking place virtually on July 28-29, 2026.

OKYO Pharma Announces Purchase of Shares by Director

2026-07-23 12:00:00

LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma's Non-Executive Director, John Brancaccio has purchased 5,000 of the Company's ordinary shares on NASDAQ at $1.48 per share, bringing his total holding to 35,201 shares.

OKYO Pharma Announces Purchase of Shares by Chief Executive Officer

2026-07-23 07:00:00

LONDON and NEW YORK, July 23, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma's Chief Executive Officer, Robert J. Dempsey, has purchased 15,000 of the Company's ordinary shares on NASDAQ at $1.54 per share.

OKYO Pharma Announces Purchase of Shares by Chairman

2026-07-22 12:00:00

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that its Chairman, Mr. Gabriele Cerrone, through Panetta Partners Ltd, an entity in which he has a beneficial interest, has increased his holdings with the purchase of 22,500 ordinary shares at $1.45 per share, bringing his total holding to 10,873,916 ordinary shares, which is 20.55% of issued share capital.

OKYO Pharma Announces Purchase of Shares by Chief Development Officer and Director

2026-07-22 10:00:00

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that Gary S. Jacob, PhD, Chief Development Officer and Director of OKYO Pharma has increased his holdings with the purchase of 3,500 of the Company's ordinary shares on NASDAQ at $1.40 per share, bringing his total holding to 112,420 ordinary shares.

OKYO Pharma Announces Purchase of Shares by Chief Medical Officer

2026-07-22 07:00:00

LONDON and NEW YORK, July 22, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced that OKYO Pharma's Chief Medical Officer, Flavio Mantelli, MD, PhD, has purchased 20,000 of the Company's ordinary shares on NASDAQ at $1.40 per share.

OKYO Pharma to Present at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference

2026-07-21 09:00:00

LONDON and NEW YORK, July 21, 2026 (GLOBE NEWSWIRE) -- OKYO Pharma Limited (Nasdaq: OKYO), a clinical-stage biopharmaceutical company developing investigational therapies for the treatment of neuropathic corneal pain (NCP) and anterior segment eye diseases, today announced a presentation at the H.C. Wainwright 6th Annual Ophthalmology Virtual Conference being held on Wednesday, July 22, 2026.

Frequently Asked Questions

What is the current OKYO Pharma Limited (OKYO) stock price?

OKYO Pharma Limited(NASDAQ:OKYO) stock price is $1.49 in the last trading session. During the trading session, OKYO stock reached the peak price of $3.33 while $1.34 was the lowest point it dropped to. The percentage change in OKYO stock occurred in the recent session was --2.61% while the dollar amount for the price change in OKYO stock was -$0.04.

OKYO's industry and sector of operation?

The NASDAQ listed OKYO is part of Biotechnology industry that operates in the broader Healthcare sector.

Who are the executives of OKYO?

Robert J. Dempsey | Chief Executive Officer & Executive Director
Michael Paul Beck | Founder
Rajkumar Patil | Chief Scientific Officer
Flavio Mantelli | Chief Medical Officer
Keeren Shah | Chief Financial Officer

How many employees does OKYO have?

Number of OKYO employees currently stands at 5. OKYO operates from 55 Park Lane, London, GL W1K 1NA, GB.

Link for OKYO official website?

Official Website of OKYO is: https://www.okyopharma.com

How do I contact OKYO?

OKYO could be contacted at phone #44 20 7495 2379 and can also be accessed through its website. OKYO operates from 55 Park Lane, London, GL W1K 1NA, GB.

How many shares of OKYO are traded daily?

The average number of OKYO shares traded daily for last 3 months was 75.05K.

What is the market cap of OKYO currently?

The market value of OKYO currently stands at $57.17M with its latest stock price at $1.49